Tag: Mogad

While over 90% of adults and children with MOGAD experience a full or near-full recovery after their first acute attack, no FDA-approved long-term preventative options exist. This has led to a major focus on research into **what is the new treatment for MOGAD** to prevent relapses and improve long-term outcomes.

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) affects approximately 20 people per million, leading to inflammatory attacks on the central nervous system. For this reason, knowing how to treat MOG antibodies is crucial for minimizing disability and managing this rare autoimmune condition.

Approximately 50% of adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) will experience a relapsing course. The treatment approach for MOGAD is highly individualized, addressing both acute inflammatory attacks and long-term relapse prevention. So, what medication is used for MOG antibody disease to manage this complex autoimmune condition? This article explores the range of pharmacological and non-pharmacological interventions used today.